In a 3‑month study of 60 people with type 2 diabetes, tirzepatide lowered blood sugar (HbA1c) and body weight while also changing how participants ate. Their overall eating‑behavior scores improved, and they felt the diet was more worthwhile, even though they reported the diet felt a bit more burdensome.

We investigated changes in eating behavior associated with the administration of tirzepatide and evaluated any changes in diet-related QOL due to tirzepatide. The study included 60 outpatients with type 2 diabetes mellitus who had been on tirzepatide for 3 months. The changes in body weight and HbA1c levels of all participants were observed for 3 months following the initiation of tirzepatide treatment. Simultaneously, we conducted a questionnaire survey that included questions on their eating behavior (Eating Behavior Questionnaire) and diet-related quality-of-Life (DDRQOL). HbA1c levels significantly reduced after the first month of administration from 7.40 ± 1.58% at the start to 6.78 ± 0.99% after 3 months (p < 0.001). Body weight also significantly decreased from 80.7 ± 13.2 kg at the start to 78.3 ± 12.9 kg after 3 months (p < 0.001). The total Eating Behavior Questionnaire score significantly reduced from 52.9 ± 10.9 points to 47.7 ± 9.9 points after 3 months (p < 0.001). There was a strong positive correlation only between the variations of the total score of the Eating Behavior Questionnaire and weight variations (r = 0.363, p = 0.005). Regarding the scores by subscales of DDRQOL, "Satisfaction with diet" changed from 75.3 ± 14.5 points at the start to 73.9 ± 14.8 points after 3 months, showing no significant changes (p = 0.335). "Burden of diet therapy" significantly increased from 50.8 ± 14.9 points to 56.1 ± 15.9 points (p = 0.002), as did "Perceived merits of diet therapy" from 57.9 ± 13.9 points to 61.8 ± 11.2 points (p = 0.035). Administration of tirzepatide improved eating behavior, leading to increased diet-related QOL and decreased HbA1c levels and body weight.